Drugs / Havrix Junior
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01379937 | Jul 2011 → Aug 2012 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01405677 Comparator | Jun 2004 → Apr 2012 | hepatitis A virus infection | Crucell Holland BV | Completed | No outcome recorded |
| Phase 3 | NCT01439360 Comparator | Oct 2011 → Oct 2014 | influenza | GlaxoSmithKline | Completed | Met primary |
| Phase 4 | NCT01196026 Comparator | Sep 2010 → May 2011 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Havrix Junior | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01439360 ↗ |
| Modality | Vaccine | “Havrix Junior vaccine” NCT01196026 ↗ |
| Route | Intramuscular | “Two intramuscular injections” NCT01196026 ↗ |